News & Highlights

[Healthcare Payer News] Sovaldi spurs call to action on high drug costs

May 21, 2014

By Anthony Brino May 21, 2014   The breakthrough hepatitis drug Sovaldi Read More

[Politico] No consensus on how to afford specialty drugs

May 21, 2014

By Brett Norman May 21, 2014 The astronomical price of a new “miracle” Read More

[Inside Health Policy] Spurred By Sovaldi’s Price, Drug Makers & Plans Consider Mortgaging Pricey Drugs

May 21, 2014

By John Wilkerson May 21, 2014   Spurred by the prospect of Sovaldi’s Read More

[Roanoke Times] The People’s Pharmacy: Will cost of cancer drugs break the bank?

May 20, 2014

By Joe and Teresa Graedon May 20, 2014   Cancer has become a cash cow for Read More

[McClatchy DC] Insurers, regulators prepare to negotiate 2015 health coverage costs

May 20, 2014

By Tony Pugh May 20, 2014 The risk pools in these 24 states need these healthy Read More

[California Health Line] High-Priced Drug Could Be Deal Changer

May 19, 2014

By George Lauer May 19, 2014   An effective, high-priced drug has Read More

[Puget Sound Business Journal] $1,000-a-pill hepatitis C drug may be too costly for Medicaid insurers

May 14, 2014

By Atia Musazay May 14, 2014   A breakthrough drug now on the market Read More

[Bloomberg Government] Backlash on Rising Drug Prices Led by Cancer Doctors, Insurers

May 7, 2014

By Robert Langreth May 7, 2014   The backlash over surging drug Read More

[Georgia Health News] Hepatitis C: The high cost of a cure

May 6, 2014

By Andy Miller May 6, 2014   Probably the biggest ethical dilemma now Read More

[Forbes] At $1,000 A Pill, Hepatitis C Drug Sovaldi Rattles Medicaid Programs

Apr 28, 2014

By Bruce Jaspen April 28, 2014   Medicaid health insurance programs for Read More

[Washington Post] An $84,000 hepatitis drug is giving states and insurers a major headache

Apr 28, 2014

By Jason Millman April 28, 2014   The new hepatitis C drug Sovaldi is Read More

[The New Yorker] BIOTECH’S HARD BARGAIN

Apr 28, 2014

BY JAMES SUROWIECKI April 28 Issue   Few people have done better in the Read More